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THE SURGICAL TREATMENT of most forms of congenital heart disease is a remarkable success story. Mortality figures are low even for complex conditions such as transposition of the great arteries and tetralogy of Fallot. Despite the immediate operative success, however, important residua, sequelae and late complications have been reported in the more common conditions (table 1) .
In this issue of Circulation, the University of Minnesota pediatric and adult cardiology groups add another chapter to reports of abnormalities after surgery for congenital heart disease.1 They investigated 11 survivors of the Fontan procedure for treatment of tricuspid atresia. Their report illustrates three recurring themes in follow-up studies for postoperative congenital heart disease patients.
First, the surgical mortality is very low, with no perioperative deaths in their 16 consecutive patients. Second, clinical assessment of cardiac status (New York Heart Association classification) reveals that most patients are asymptomatic -nine of 13 (69%) in their series -or have only minimal symptoms. Third, with continued follow-up and postoperative investigations, significant residua, sequelae and complications become apparent (table 2) . Of particular interest are the late deaths (two of 16 died suddenly, suggesting dysrhythmia), the low cardiac index at rest, and the abnormal response to exercise. Although the numbers of patients are small, the message seems clear: In this group of postsurgical patients, cardiac performance is suboptimal and the incidence of sudden death (possibly due to dysrhythmia) is high. These latter problems (dysrhythmia and abnormal cardiac performance) apply to postoperative tetralogy and transposition patients and suggest that similar mechanisms may play a role in such abnormalities in these cyanotic patient groups (table 3) .
How do the data regarding the Fontan operation guide the physician attempting to provide optimal care to his or her patient with tricuspid atresia? As with most therapy for complex congenital heart disease, the answers are not clear. In certain subsets of patients, particularly those who fulfill Fontan's criteria for an optimal candidate for his procedure,2 the postoperative results appear to be good.3 8 These ideal patients, however, would probably also do excep-tionally well with a shunt procedure.9-1" There are no data that compare similar subsets of tricuspid atresia patients after a Fontan vs a shunt or multiple shunts in terms of longevity, morbidity and cardiovascular performance. The many unanswered questions in the treatment of tricuspid atresia patients (table 4) indicate the need for detailed investigations and careful analysis of long-term follow-up data for patients after operations for congenital heart disease.
For future follow-up studies for postoperative patients, important areas of concern are listed in table 5. First, detailed quantitative preoperative data must be available for comparisons to allow proper assessment of perioperative events that could influence outcome. Second, perioperative data must be as detailed as possible. With recent improvements in methods for intraoperative myocardial protection, many studies showing postoperative alterations in ventricular function or dysrhythmia may not be applicable and probably should not be exclusively used in current decision-making regarding therapy until corroborative evidence is available on patients operated upon with current techniques for ischemic protection of the heart during surgery. Third, detailed postoperative investigations should be performed and, in most patients, should be delayed for at least 6-12 months after repair unless signs and symptoms indicate the need for earlier study. Cardiovascular performance should be assessed both at rest and with exercise or afterload stress.
In obtaining these postoperative data, who should have a postoperative catheterization? The answer continues to change. Echocardiography and radionuclide angiography provide much of the information needed for a complete postoperative evaluation. However, further correlative studies are needed to compare catheterization and noninvasive assessments for different subsets of postoperative patients in order to clarify which patients will require catheterization for a comprehensive evaluation.
What are some of the unresolved problems still facing the physician who treats patients with congenital heart disease? A partial list is shown in table 6. There is still much to be learned.
Finally, in dealing with complex congenital heart disease, postoperative abnormalities may be inevitable in conditions in which reparative or palliative rather than corrective more properly describes the operative options. The task at hand for surgeons, pediatric cardiologists and adult cardiologists is to continue to evaluate treatment practices critically with extended longitudinal follow-up and detailed postop- VSD; residual or recurrent stenosis; pulmonary regurgitation; ventricular dysfunction; tricuspid regurgitation; increased Rp (usually in patients with prior shunt procedure) All of those listed for tetralogy plus conduit stenosis Abbreviations: VSD = ventricular septal defect; CHF = congestive heart failure; Rp = pulmonary vascular resistance; AV = atrioventricular; RV = right ventricular. 
